Chemoprophylaxis of bacterial meningitis by SCHAAD, URS B.
Leading articles 131
for treatment by passive immunization Trans-
actions of the Royal Society of Tropical Medicate
and Hygiene 7S
Jarhling, P. B., Peters, C. J. & Stephen, E L. (1984)
Enhanced treatment of Lassa fever by immune
plasma combined with nbavinn in cynomolgus
monkeys. Journal of Infectious Diseases 149,
420-7.
Kende, M , Schroit, A., Rill, W. & Canonico, P G.
(1983). Treatment of Rift Valley fever virus
(RVFV>infected swiss mice with liposome-encap-
sulated lipophylk muramyl dipeptide (LE-MDP)
23rd Interscience Conference on Antimicrobial
Agents and Chemotherapy, Las Vegas Abstract
No. 153, p 108.
Levin, M J., Zaia, J. A., Preblud, S R. & Arbeit,
R A. (1981). Human immunoglobulin in the pre-
vention and treatment of viral diseases. In
Immunochemotherapy. A Guide to Immunoglobulin
Prophylaxis and Therapy (Nydegger, v. E , ed.),
pp 299-311 Academic Press, New York
Levy, H. B & Riley, F. L (1983) A comparison of
immune modulating effects of interferon and intcr-
feron induccrs. In Lymphokines Vol 8, (Openheim
J. & Pick, A eds), pp. 303-22 Academic Press,
New York.
Luscn, B J., Canonico, P G & Huggins, J W
(1984) Synergistic antiviral interactions of alpha
and gamma human interferons in vitro. 24th Inter-
national Conference on Antimicrobial Agents and
Chemotherapy, Washington, D C. Abstract No
Maiztequi, J. 1. (1979). Efficacy of immune plasma in
treatment of Argentine hemorrhagic fever and
association between treatment and a late neuro-
logical syndrome Lancet ii, 1216-17.
McCormick, J. B. (1984). Intravenous nbavinn
therapy for acute Lassa fever in humans In The
Clinical Applications of Ribavirm, Smith, R A ,
ed.), Academic Press, London & New York
Reynolds, J A., Kastello, M D , Harrington, D G ,
Crabbs, C L , Peters, C. J., Jemski, J V , Scott,
G. H & DiLuzio, N. R (1980). Glucan-induced
enhancement of host resistance to selected infec-
tious diseases. Infection and Immunology 30, 51-7
Wilson, S Z., Knight, V , Wyde, P R , Drake, S. &
Couch, R. B. (1980) Amantadine and nbavinn,
aerosol treatment of influenza A and B infection in
mice. Antimicrobial Agents and Chemotherapy 17,
642-8.
Chemoprophylaxis of bacterial meningitis
Bacterial meningitis remains a life-threatening
infection at any age. Approximately 80% of
the patients belong to the paediatnc age group
and more than half of these children are less
than two years old. Vaccines effective against
all types of the three principal pathogens—
Haemophilus tnfluenzae, Netsseria mentngitidis,
and Streptococcus pnewnoniae—and immuno-
genic at any age including young infants, are
the ultimate goal in order to reduce or even
eliminate morbidity and mortality of this
infection (Schaad, 1982, 1984). However, the
currently available capsular polysaccharide
preparations are far from such ideal vaccines
(Makela, 1982; Douglas el al.. 1983; Lepow &
Gold, 1983; Hill, 1983; Peltola et al.. 1984).
Close contacts of patients with invasive H.
tnfluenzae type b or meningococcal disease
show a higher prevalence of nasopharyngeal
carriage and are at considerably increased risk
of contracting the disease (The Meningococcal
Disease Surveillance Group, 1976; Ward et al.,
1979; Shapiro, 1982). Effective eradication of
the nasopharyngeal bacteria by antimicrobial
agents is possible. These facts explain the inter-
est in chemoprophylaxis for the prevention of
secondary cases in close contacts of patients
with bacterial meningitis.
The key issue in the management of contacts
remains clear education as to the need for close
and careful surveillance because chemoprophy-
laxis will never result in absolute prevention
of secondary cases. Throat or nasopharyngeal
cultures do not contribute to the identification
or management of contacts (Schaad, 1982,
1984).
The attack rate in close contacts of patients
with meningococcal disease (meningitis or
meningococcaemia) is 400 to 1200 times that of
the general population (The Meningococcal
Disease Surveillance Group, 1976; Shapiro,
1982; Peltola, 1983). Young children are at
greatest risk, but secondary meningococcal dis-
ease occurs in all age groups. The candidates
for prophylaxis are persons of all ages after
contact with a case of invasive meningococcal
infection within the week prior to the onset of
disease in the household, day-care centre, mili-
tary barracks or chronic care institution, and
after intimate contact such as mouth-to-mouth
resuscitation or kissing. Normal contact at
work, at school, and by medical personnel does
not represent a significant risk and does not
require prophylaxis. Since the index patient
often continues to be colonized with meningo-
cocci despite clinical cure and may therefore
reintroduce the organism to his close contacts,
the patient should probably also receive
adequate chemoprophylaxis before discharged
from the hospital. Before the emergence of
sulphonamide-resistant meningococci, prophy-
laxis with sulphonamides was clearly effective
both in preventing disease and eradicating
the earner state (Glasgow, 1980). Today,
in non-endemic areas, approximately 25% of
meningococci causing meningitis are resistant
to sulphonamides. Penicillin, ampicillm, eryth-
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romycin, tetracycline, chloramphenicol and
cephalexin do not reliably eliminate naso-
pharyngeal colonization of meningococci, but
minocycline and rifampicin are 80 to 90%
effective. The high incidence of vestibular
reactions associated with minocycline makes its
use as prophylactic agent problematic. Thus
despite potential emergence of resistance, poss-
ible side effects and drug costs, rifampicin
represents the best choice for prophylaxis of
meningococcal disease at present unless the
strain in the index patient is known to be sensi-
tive to sulphonamide. Both in Europe and
North America, rifampicin doses of lOmg/kg
(maximum, 600 mg) given every 12 h are
recommended for two to three days, the first
dose given as soon as possible after diagnosis of
the index case (Glasgow, 1980; Lambert, 1984;
Schaad, 1982, 1984).
The rate of disease in previously healthy,
close contacts of a patient with pneumococcal
meningitis is not reported to be increased, and
chemoprophylaxis is not necessary. However,
predisposing factors for invasive pneumococcal
diseases such as anatomical or immunological
defects are well known and appropriate
prophylaxis with vaccination and/or penicillin
is indicated (Klein, 1981).
At present chemoprophylaxis of//, influenzae
type b meningitis is a hotly debated issue.
Recent reports from the United States demon-
strated that household and day-care centre
contacts of H. influenzae type b meningitis are
at increased risk of developing the infection
(Ward et at.. 1979; Granoff & Daum, 1980;
Band, 1981; Shapiro, 1982). Over 50% of
secondary cases occur in the first week after
hospitalization of the index patient. In the age
groups of less than two years and of two to four
years, the attack rates were 200- to 400-fold
higher than endemic rates in open populations.
In contrast, secondary H. influenzae type b
disease was rare in close contacts older than
four years of age. Therefore, the candidates for
prophylaxis are children less than four years of
age after contact in the household, day-care
centre or chronic care institution. Because
asymptomatic earners of any age may spread
the bacteria to susceptible young children,
eradication of nasopharyngeal colonization
in alt' household members and day-care OT
institutional workers should theoretically be
attempted. Chemoprophylaxis is also desirable
for the index patients because they may remain
colonized after adequate therapy for menin-
gitis. Although several antimicrobial agents are
effective against H. influenzae in vitro, many
have been ineffective in eliminating naso-
pharyngeal carriage. These include ampicillin,
ccfaclor, erythromycin-sulfisoxazole, trimetho-
prim-sulphamethoxazole and trimethoprim-
rifampicin. The majority of studies of
rifampicin at 20mg/kg orally in a single daily
dose (maximum, 600 mg) for four days report a
90 to 95% efficacy in the eradication of naso-
pharyngeal H. influenzae type b colonization in
household, day-care centre and institutional
contacts (Shapiro & Wald, 1980; Murphy et at.,
1983). In a multicentre field trial coordinated
by the US Centers for Disease Control, house-
hold and day-care centre contacts were
randomized to receive rifampicin prophylaxis
or placebo. There was a significant dimin-
ution in secondary cases among rifampicin
recipients—no case among the 1112 rifampicin
treated contacts versus four secondary cases
among the 765 placebo-treated contacts (Band
et at., 1984). Based on this single pre-
liminary experience the American Academy of
Pediatrics (Committee on Infectious Diseases)
formulated recommendations for the use of-
rifampicin prophylaxis of contacts of patients
with H. influenzae infection (AAP, Red Book
1982) which recently were revised (AAP, 1984).
This latest policy does not now include day-
care centre and nursery school contacts
('individual' approach) and is concentrated on
all contacts in households where there are
children (other than the index case) less than
four years old.
There are several factors inherent in
rifampicin prophylaxis which in the opinion of
many specialists in paediatric infectious dis-
eases must exclude its routine recommendation
at the present time (Shapiro, 1982; Daum &
Halsey, 1982; Mann & Hull, 1983; Murphy el
at., 1983; Schaad, 1984): (1) Extended con-
trolled experience on both epidemiology and
rifampicin prophylaxis is needed from different
countries including Western Europe, where
day-care centres and nursery schools are less
popular than in North America. (2) Failure
of prophylaxis and recolonization at one to
four weeks after rifampicin administration are
most common in young children who are at
greatest risk for disease. (3) Emergence of
rifampicin-resistant H. influenzae type b strains
after prophylaxis does occur. (4) Very large
numbers of contacts should theoretically
receive chemoprophylaxis in order to reduce
secondary cases optimally. (5) Prevention and
eradication of colonization may abort the
physiological immunizing effect of inapparent
infection. (6) Possible side effects and drug
costs of nfampicin represent important logistic
problems for widespread use of this agent.
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Based on these six points it is concluded, that
routine use of rifampicin for prevention of
secondary H. influenzae type b disease in close
contacts is not indicated. Close and careful
surveillance of the exposed children is essential.
Prophylactic rifampicin may be prescribed for
all household contacts (as soon as possible)
and the index patient (before hospital dis-
charge) if there are household members of less
than four years of age and if there are special
circumstances such as an already damaged
child, profound fear or extremely crowded
conditions.
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Hvpoprothrombinemia caused by cephalosporins
Cephalosporin-induced hypoprothrombinemia
has been reviewed about two years ago in this
Journal (Smith & Lipsky, 1983). New infor-
mation has rapidly accumulated since then, and
many problems which allowed only speculation
one year ago, can now be discussed on the basis
of firm evidence. This leading article addresses
the problem of whether cephalosporins cause
hypoprothrombinemia by interfering with colo-
nic microflora or with hepatic metabolism of
vitamin K.
Clinical observations (Holt, Gorrochategui
& Perez, 1981; Pakter el al., 1982; Schwigon &
